These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 25651188)
1. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. Tinsley J; Robinson N; Davies KE J Clin Pharmacol; 2015 Jun; 55(6):698-707. PubMed ID: 25651188 [TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy. Ricotti V; Spinty S; Roper H; Hughes I; Tejura B; Robinson N; Layton G; Davies K; Muntoni F; Tinsley J PLoS One; 2016; 11(4):e0152840. PubMed ID: 27055247 [TBL] [Abstract][Full Text] [Related]
3. A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet. Muntoni F; Tejura B; Spinty S; Roper H; Hughes I; Layton G; Davies KE; Harriman S; Tinsley J Clin Pharmacol Drug Dev; 2019 Oct; 8(7):922-933. PubMed ID: 30650257 [TBL] [Abstract][Full Text] [Related]
4. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. Taylor L; Gidal B; Blakey G; Tayo B; Morrison G CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683 [TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study. Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects. Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor. Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370 [TBL] [Abstract][Full Text] [Related]
8. Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age. Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E Clin Ther; 2016 Jan; 38(1):39-52. PubMed ID: 26581327 [TBL] [Abstract][Full Text] [Related]
9. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550 [TBL] [Abstract][Full Text] [Related]
11. Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study. Ito M; Tauscher-Wisniewski S; Smulders RA; Wojtkowski T; Yamada A; Koibuchi A; Uz T; Marek GJ; Goldwater RD Muscle Nerve; 2022 Jan; 65(1):110-120. PubMed ID: 34642949 [TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study. Chu NN; Huang K; Que LL; Ding Y; Gu XH; Zhang L; Wang JK; Chen XP; Sun ZG; He Q Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):509-521. PubMed ID: 35429285 [TBL] [Abstract][Full Text] [Related]
13. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects. Takizawa M; Cerneus D; Michon I; Rijnders S; van der Heide D; Meijer J; Stoelzel M; Sato Y Adv Ther; 2020 Sep; 37(9):3878-3900. PubMed ID: 32681461 [TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-Ascending Doses of Sunobinop in Healthy Participants. Cipriano A; Kapil RP; Zhou M; Shet MS; Whiteside GT; Willsie SK; Harris SC Clin Pharmacol Drug Dev; 2024 Jul; 13(7):790-800. PubMed ID: 38476082 [TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers. Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605 [TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study. Derks M; Anzures-Cabrera J; Turnbull L; Phelan M Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361 [TBL] [Abstract][Full Text] [Related]
17. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study. Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483 [TBL] [Abstract][Full Text] [Related]
19. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers. Xiao F; Zhang F; Zhang LL; Wei W Eur J Clin Pharmacol; 2018 Jan; 74(1):69-77. PubMed ID: 29051989 [TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects. Wang S; Chen G; Merlo Pich E; Affinito J; Cwik M; Faessel H Br J Clin Pharmacol; 2021 Nov; 87(11):4354-4365. PubMed ID: 33837574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]